There are now 173 AI-discovered drug programs in active development. More than 200 AI-enabled therapeutics are in clinical testing, with 15 to 20 expected to enter pivotal trials in 2026 alone. FDA has authorized over 1,350 AI-enabled devices — roughly double the number in 2022. The clinical pipeline is here. The regulatory framework is catching up. And the legal function at most biotech companies is still organized around the world that existed before all of this.
I have been watching this gap widen for the last two years. Companies that are genuinely built on AI/ML — where the algorithm runs the discovery, clinical design, and regulatory strategy — are running their legal functions on templates built for traditional small molecule or biologics companies. The IP strategy does not account for the inventorship questions that AI-assisted discovery creates. The vendor agreements do not address what happens when the AI platform produces output that ends up in an FDA submission and turns ou…


